Skip to Content

Inrebic Approval History

FDA Approved: Yes (First approved August 16, 2019)
Brand name: Inrebic
Generic name: fedratinib
Dosage form: Capsules
Company: Celgene Corporation
Treatment for: Myelofibrosis

Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.

Development History and FDA Approval Process for Inrebic

DateArticle
Aug 16, 2019Approval FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis
Jun  3, 2019Celgene Updated Analysis of Jakarta2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
Mar  5, 2019U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide